comparemela.com

Latest Breaking News On - Rashid sayyid - Page 1 : comparemela.com

ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study

ASCO 2024 phase III STELLAR-304 trial, combination of zanzalintinib (XL092) plus nivolumab in patients with non-clear cell renal cell carcinoma (nccRCC), tyrosine kinase inhibitor (TKI) sunitinib.

United statesSumantak palSumanta palAmerican society of clinical oncologyDepartment of medical oncologySociety of urologic oncologyUniversity of torontoTherapeutics researchCity of hope comprehensive cancer centerClinical oncologyAnnual meetingSouth americaNorth americaMedical oncologyHope comprehensive cancer centerRashid sayyid

ASCO 2024: ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Spaces

discussed ADT-sparing approaches in both the metastatic castrate sensitive and resistant settings.

United statesNew yorkMemorial sloan kettering cancer centerKaren autioKarena autioEuropean association of urologyAmerican society of clinical oncologyOncology groupNational comprehensive cancer networkUniversity of torontoSociety of urologic oncologyGenitourinary oncologist early drug development specialistAmerican urological associationClinical oncologyAnnual meetingProstate cancer consensus conference

ASCO 2024: Belzutifan in Patients with Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 2 LITESPARK-013 Study

ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

United statesGeorgetown universityDistrict of columbiaMichael atkinsMichaelb atkinsUniversity of torontoGeorgetown lombardi comprehensive cancer centerDepartment of medical oncologyDatabase consortiumGeorgetown university medical centerMerck sharp domeSociety of urologic oncologyInternational metastaticAmerican society of clinical oncologyClinical oncologyAnnual meeting

ASCO 2024: A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)

ASCO 2024 results of a multicenter phase II trial of modified FOLFIRINOX for the first-line treatment of advanced urachal cancer (ULTMA; KCSG GU20-03), Urachal cancer is a rare malignancy accounting for 1% of bladder cancers.

United statesSouth koreaSoult ukpyolsiJae lyun leeMd anderson cancer centerSociety of urologic oncologyAmerican society of clinical oncologyUniversity college of medicineAsan medical centerUniversity of torontoClinical oncologyAnnual meetingUniversity collegeRashid sayyidUrologic oncologyClinical fellow

ASCO 2024: Camrelizumab plus Apatinib for Previously Treated Advanced Adrenocortical Carcinoma: A Single-Arm, Open-Label, Phase 2 Trial

advanced adrenocortical carcinoma, camrelizumab, Apatinib, Camrelizumab plus Apatinib.

United statesZhigong weiSociety of urologic oncologyAmerican society of clinical oncologyUniversity of torontoSichuan universityDepartment of biotherapyCancer centerClinical oncologyAnnual meetingWest china hospitalRashid sayyidUrologic oncologyClinical fellowAdvanced adrenocortical

vimarsana © 2020. All Rights Reserved.